"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 6 | 6 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 7 | 9 |
| 2003 | 1 | 2 | 3 |
| 2004 | 3 | 5 | 8 |
| 2005 | 3 | 3 | 6 |
| 2006 | 1 | 4 | 5 |
| 2007 | 3 | 6 | 9 |
| 2008 | 4 | 5 | 9 |
| 2009 | 2 | 9 | 11 |
| 2010 | 7 | 6 | 13 |
| 2011 | 0 | 10 | 10 |
| 2012 | 5 | 3 | 8 |
| 2013 | 7 | 8 | 15 |
| 2014 | 4 | 7 | 11 |
| 2015 | 7 | 10 | 17 |
| 2016 | 9 | 4 | 13 |
| 2017 | 7 | 3 | 10 |
| 2018 | 2 | 12 | 14 |
| 2019 | 5 | 13 | 18 |
| 2020 | 3 | 17 | 20 |
| 2021 | 3 | 10 | 13 |
| 2022 | 1 | 16 | 17 |
| 2023 | 0 | 11 | 11 |
| 2024 | 3 | 6 | 9 |
| 2025 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Successful Treatment of Double-Positive Rapidly Progressive Glomerulonephritis: A Case Report. J Investig Med High Impact Case Rep. 2025 Jan-Dec; 13:23247096251365418.
-
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax. 2025 07 15; 80(8):540-546.
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
-
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy. Haematologica. 2025 Nov 01; 110(11):2635-2646.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626.
-
Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15; 131(2):e35713.
-
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2025 May; 77(5):571-581.